Please assess the completion status of the following clinical trial:

Trial Title: Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prepubertal age~* Prepubertal characteristics~* Non GH deficient~* Short children (height \< -2.5 SDS)~* Born SGA (birth height \< -2 SDS)~* Parental height adjusted (\< -1 DS)~* No rhGH treatment before inclusion~Exclusion Criteria:~* ALLERY to rhGH or excipients~* Small height etiologies~* Cancer or cancer treatment ongoing~* Drugs interference with growth~* Mental impairment~* Hypertrophic cardiopathy impairment~* Hypertension not under controlled~* Intra cranial hypertension not controlled~* Diabetes and hyperglycaemia without diabetes~* Dyslipidemia~* Hepatitis~* Kidney failure~* Chromosomic aberration and/or genetic disorders (except Silver Russel Syndrome)~* No social security~* State of health in worst conditions after cardiac surgery, polytraumatism

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): the recommended dose in the EU of rhGH (Norditropine SimpleXx®)
- 2 (Type: ACTIVE_COMPARATOR): the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).